IP Library Granted Patent US 8,975,403
Granted Patent B2
US 8,975,403 · App. 14/189,706 · Granted Mar 10, 2015

Process for producing substituted benzo[F]imidazo[1,2-A]quinoxalin-3(11H)-ones

Inventors: Satoshi Inouye (Kanagawa, JP); Yuiko Miura (Kanagawa, JP); Suguru Yoshida (Tokyo, JP); Takamitsu Hosoya (Tokyo, JP)
Assignees: JNC Corporation; National University Corporation Tokyo Medical and Dental University
C07D487/04C07D241/38C07D241/44C07D241/54
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,975,403
App. No.
14/189,706
Granted
Mar 10, 2015
Kind
B2
Abstract

A simple process for producing v-coelenterazine compounds has been desired. Described is a process for producing a v-coelenterazine compound represented by general formula (II) comprising (1) the step of reacting a compound of general formula (VIII) with a methyltriphenylphosphonium salt in the presence of a base to give a compound represented by general formula (IX), (2) the step of performing a ring-closing metathesis reaction on any one selected from the group consisting of the compound represented by general formula (IX) and a compound of general formula (X) which is the compound of general formula (IX) wherein the amino is protected with R 5 , and then deprotecting R 4 and, if any, R 5 to give a v-coelenteramine compound represented by general formula (XIV), and (3) the step of reacting the compound of general formula (XIV) with a compound represented by general formula (XV) to give the compound of general formula (II).

Claims (21)

1. A process for producing a v-coelenterazine compound represented by formula (II):

wherein:

R 1 is hydrogen; a halogen; an unsubstituted aryl; an aryl substituted with at least one substituent selected from the group consisting of a halogen, hydroxy, an alkyl having 1 to 6 carbon atoms, an alkoxy having 1 to 6 carbon atoms, an amino and a dialkylamino having 1 to 6 carbon atoms; an unsubstituted arylalkyl; an arylalkyl substituted with at least one substituent selected from the group consisting of a halogen, hydroxy, an alkyl having 1 to 6 carbon atoms, an alkoxy having 1 to 6 carbon atoms, an amino and a dialkylamino having 1 to 6 carbon atoms; an unsubstituted arylalkenyl; an arylalkenyl substituted with at least one substituent selected from the group consisting of a halogen, hydroxy, an alkyl having 1 to 6 carbon atoms, an alkoxy having 1 to 6 carbon atoms, an amino and a dialkylamino having 1 to 6 carbon atoms; an unsubstituted alkyl; an alkyl substituted with an alicyclic group; an unsubstituted alkenyl; an alkenyl substituted with an alicyclic group; an alicyclic group; a heterocyclic group; an unsubstituted alkynyl; or an alkynyl substituted with an alicyclic group,

each of R 2 and R 3 independently represents hydrogen, hydroxy, a halogen, an unsubstituted alkyl having 1 to 4 carbons; an alkyl having 1 to 4 carbon atoms substituted with an alicyclic group, trifluoromethyl or an alkoxy,

which comprises:

(1) reacting a compound represented by formula (VIII):

wherein R 1 is the same as defined above; and R 4 is a protecting group selected from the group consisting of methyl, methoxymethyl, tetrahydropyranyl, benzyl, 4-methoxybenzyl, tert-butyldimethylsilyl, trimethylsilyl, triethylsilyl, phenyldimethylsilyl, tert-butyldiphenylsilyl, and triisopropylsilyl;

with a methyltriphenylphosphonium salt in the presence of a solvent and a base to give a compound represented by formula (IX):

wherein R 1 and R 4 are the same as defined above;

(2) performing a ring-closing metathesis reaction on any one selected from the group consisting of the compound represented by formula (IX) and a compound represented by formula (X) which is prepared by protecting the amino in formula (IX) with R 5 :

wherein R 1 and R 4 are the same as defined above; and R 5 is a protecting group selected from the group consisting of acetyl, benzoyl, p-tosyl, tert-butoxycarbonyl and benzyloxycarbonyl

in the presence of a solvent and a catalyst, and then deprotecting R 4 and, if any, R 5 to give a v-coelenteramine compound represented by formula (XIV):

wherein R 1 is the same as defined above; and,

(3) reacting the compound represented by formula (XIV) with a compound represented by formula (XV):

wherein each of R 2′ and R 3′ independently represents hydrogen, hydroxy, an alkoxy, a halogen, a hydrocarbon group, or a hydroxy group protected with a protecting group selected from the group consisting of tert-butyldimethylsilyl, methoxymethyl, tetrahydropyranyl, trimethylsilyl, triethylsilyl, phenyldimethylsilyl, tert-butyldiphenylsilyl, and triisopropylsilyl to give the compound represented by formula (II).

2. The process according to claim 1 , wherein at least one base selected from the group consisting of n-butyl lithium, potassium tert-butoxide, sodium methoxide, sodium ethoxide and lithium diisopropylamide is used as the base in step (1).

3. The process according to claim 1 , wherein at least one solvent selected from the group consisting of tetrahydrofuran, diethyl ether, cyclopropyl methyl ether, tert-butyl methyl ether, dioxane and toluene is used as the solvent in step (1).

4. The process according to claim 1 , wherein the reaction temperature and reaction time in step (1) are set at 0° C. to 40° C. for an hour to 4 hours.

5. The process according to claim 1 , wherein a second generation Hoveyda-Grubbs catalyst is used as the catalyst for the ring-closing metathesis reaction in step (2).

6. The process according to claim 1 , wherein at least one solvent selected from the group consisting of dichloroethane, dichloromethane, chloroform, trichloroethane, tetrachloroethane, benzene, toluene, xylene, monochlorobenzene, dichlorobenzene, hexane, heptane, octane, tetrahydrofuran, dioxane, diethyl ether, dibutyl ether, diisopropyl ether and dimethoxyethane is used as the solvent for the ring-closing metathesis reaction in step (2).

7. The process according to claim 1 , wherein the reaction temperature and reaction time of the ring-closing metathesis reaction in step (2) are set at 25° C. to 110° C. for an hour to 48 hours.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 13, 2017
From: NATIONAL UNIVERSITY CORPORATION TOKYO MEDICAL AND DENTAL UNIVERSITY
To: JNC CORPORATION
Reel/Frame 041553/0874 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 9, 2017
From: INOUYE, SATOSHI; MIURA, YUIKO; YOSHIDA, SUGURU; HOSOYA, TAKAMITSU
To: JNC CORPORATION; NATIONAL UNIVERSITY CORPORATION TOKYO MEDICAL AND DENTAL UNIVERSITY
Reel/Frame 041519/0805 →
Priority Claims (1)
JP 2011-050487 · Mar 8, 2011 · national
Continuity (2)
Division 13412682 · Mar 6, 2012
Related Publication 20140206868A1 · Jul 24, 2014